Allogene Therapeutics - ALLO Stock Forecast, Price & News

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. JMP Securities reiterated a "buy" rating and issued a $23.00 price objective on shares of Allogene Therapeutics in a research note on Monday, April 11th. Raymond James reduced their price objective on shares of Allogene Therapeutics from $36.00 to $13.00 in a research note on Thursday, May 5th. Robert W. Baird assumed coverage on shares of Allogene Therapeutics in a research note on Thursday, June 2nd. They issued a "neutral" rating and a $11.00 price objective for the company. Finally, The Goldman Sachs Group upgraded shares of Allogene Therapeutics from a "neutral" rating to a "buy" rating and raised their price objective for the company from $9.00 to $32.00 in a research note on Friday, July 15th. Two research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $28.17.

Allogene Therapeutics Trading Down 5.8 %

Shares of NASDAQ:ALLO traded down $0.93 during midday trading on Tuesday, reaching $15.03. 1,843,185 shares of the stock were exchanged, compared to its average volume of 1,869,377. The company has a market capitalization of $2.16 billion, a P/E ratio of -7.25 and a beta of 0.55. Allogene Therapeutics has a 52-week low of $6.43 and a 52-week high of $27.86. The stock has a 50 day moving average price of $11.65 and a 200-day moving average price of $9.94.

Insider Transactions at Allogene Therapeutics

In other news, Director Owen N. Witte sold 10,000 shares of Allogene Therapeutics stock in a transaction dated Wednesday, June 22nd. The shares were sold at an average price of $11.76, for a total transaction of $117,600.00. Following the completion of the sale, the director now directly owns 233,271 shares in the company, valued at $2,743,266.96. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, Director Owen N. Witte sold 10,000 shares of the firm's stock in a transaction that occurred on Wednesday, June 22nd. The shares were sold at an average price of $11.76, for a total value of $117,600.00. Following the sale, the director now directly owns 233,271 shares of the company's stock, valued at $2,743,266.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CMO Rafael Amado sold 11,500 shares of the firm's stock in a transaction that occurred on Thursday, May 19th. The stock was sold at an average price of $7.40, for a total transaction of $85,100.00. Following the completion of the sale, the chief marketing officer now directly owns 546,257 shares in the company, valued at $4,042,301.80. The disclosure for this sale can be found here. Insiders sold a total of 27,500 shares of company stock worth $271,880 over the last ninety days. 26.30% of the stock is currently owned by corporate insiders.